TL;DR
DSIP is a nine-amino-acid peptide first isolated in rabbit sleep experiments in the 1970s. Early work linked it with slow-wave EEG activity, but later human findings were small, mixed and difficult to reproduce. No confirmed receptor or definitive mechanism has been established. It should be understood as a historical, uncertain research peptide rather than a proven sleep treatment.
What is DSIP?
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits kept in an induced sleep state. The
foundational discovery was published in 1977 by Schoenenberger GA and Monnier M in the Proceedings of the National Academy of Sciences, describing a peptide associated with delta-wave (slow-wave) EEG activity — the basis for its name. Early research through the late 1970s and 1980s explored possible roles for DSIP in sleep regulation, circadian rhythm, and modulation of the stress/HPA axis.
DSIP has a mixed and inconsistent replication history. Several follow-up human studies conducted through the 1980s and 1990s failed to consistently replicate the sleep-promoting effects reported in early work, and no receptor or definitive mechanism of action was ever conclusively identified for DSIP — unlike, for example, ghrelin-receptor peptides with a clear binding target. By the 1990s and 2000s, scientific interest in DSIP declined markedly due to these inconsistent findings and the inability to establish a clear mechanism, and some researchers questioned whether DSIP functions as a discrete "sleep hormone" at all, versus a more general stress-modulating or neuromodulatory peptide. This guide presents that uncertainty rather than promoting DSIP as an established sleep aid. This guide is for educational and research purposes only. Not medical advice.
How strong is the evidence?
| Evidence Type |
Status |
| Human RCT |
✔ |
| Observational |
✔ |
| Animal Studies |
✔ |
| In Vitro |
✗ |
| Regulatory Approval |
✗ |
Small human studies exist, but they are older, limited in scale, and have produced inconsistent results across independent replications. In vitro mechanistic work is minimal to absent given that no confirmed receptor target has been established. No regulatory approval exists for DSIP for any indication.
How does DSIP work?
Unlike well-characterised secretagogue or receptor-targeted peptides, DSIP's mechanism of action was never conclusively established. Researchers in the years following its discovery proposed several hypothesised interactions — including modulation of GABAergic signalling, involvement in HPA-axis regulation (particularly cortisol modulation), and possible interplay with opioid or other neuromodulatory systems — but none of these pathways has been confirmed as the definitive mode of action.
This absence of a clear, reproducible mechanism is itself one of the most significant limitations of the DSIP literature. Without an identified receptor or binding target, it has been difficult for researchers to design targeted follow-up studies or to explain why early findings were not consistently replicated in later, better-controlled trials. Any discussion of DSIP's mechanism should therefore be understood as hypothesis-level rather than established pharmacology.
What has DSIP been studied for?
Sleep Architecture & Delta-Wave Research
The original rabbit studies by Schoenenberger and Monnier reported induction of delta-wave (slow-wave) EEG activity following administration of the isolated peptide, giving DSIP its name and forming the basis for early interest in it as a potential sleep-regulating compound.
Replication Challenges & Inconsistent Findings
This is a central and necessary section of the DSIP research record: numerous follow-up studies in the 1980s and 1990s attempting to replicate the early sleep-promoting findings in humans produced inconsistent or null results. Effect sizes varied considerably between studies, some found no measurable improvement in sleep quality or architecture, and the lack of a confirmed mechanism made it difficult to reconcile these discrepancies. This replication difficulty is a primary reason scientific interest in DSIP declined substantially by the 1990s–2000s.
Stress and HPA-Axis Modulation Research
Some research explored whether DSIP affects the hypothalamic-pituitary-adrenal (HPA) axis and cortisol secretion, framing it as a possible stress-modulating peptide rather than a sleep-specific one. Well-controlled human trials have not confirmed those exploratory findings.
Circadian Rhythm Research
A smaller body of work examined whether DSIP administration influenced circadian rhythm markers. As with the sleep-architecture research, results across studies were variable, and no consistent circadian effect has been firmly established in the literature.
What did the studies actually find?
| Study / Model |
Reported Effect |
| Schoenenberger GA, Monnier M (1977) — Rabbit model |
Isolation of a peptide from cerebral venous blood associated with induction of delta-wave (slow-wave) sleep activity. |
| Subsequent small human trials (1980s–1990s) |
Variable and inconsistent sleep-quality outcomes; several studies failed to replicate the original delta-wave findings. |
| Later controlled human trials |
Inconsistent or null findings reported by multiple independent groups, contributing to declining research interest. |
What side effects were reported?
- Transient dizziness (reported in some older study subjects)
- Mild headache (infrequent, reported in limited historical literature)
Modern safety data for DSIP is lacking. The available literature comes largely from small studies conducted decades ago, and no large modern trial has updated that picture.
DSIP at a glance
- CAS Number
- 62568-57-4
- Molecular Formula
- C33H49N13O15S
- Molecular Weight
- Approximately 847.86 g/mol
- Half-Life
- Short, approximately a few minutes in circulation (rapidly degraded) — cited in the literature as a limitation of proposed therapeutic use
- Synonyms
- Delta Sleep-Inducing Peptide, DSIP
- Research Classification
- Nonapeptide, Historical Sleep/Neuromodulatory Research Compound
The research this page cites
- Schoenenberger GA et al. 1977 — Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. — Proceedings of the National Academy of Sciences — [Animal / Discovery]
- Graf MV et al. 1986 — Delta-sleep-inducing peptide (DSIP): an update. — Peptides — [Review, discusses replication issues]
This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.
